FINHUB Insights

IDXX · Q3 FY25 · Jul 1 – Sep 30, 2025

Idexx Laboratories Q3 FY25: where the revenue came from and where it went

Idexx Laboratories Q3 FY25: revenue $1.1B (+13% year over year). Net profit $0.3B. Largest cohort IDEXX VetLab consumables $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 3, 2025 10-Q
Sankey diagram of Idexx Laboratories's income statement for Q3 FY25: revenue of $1.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.1B +13% year over year
Gross profit$0.7B 62% margin
Operating profit$0.4B 32% margin
Net profit$0.3B 25% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 1.1 100% +13%
IDEXX VetLab consumables 0.4 36% +18%
Reference laboratory diagnostic… 0.4 36% +10%
Rapid assay products 0.1 9% −4%
Recurring revenue 0.1 9% +10%
Water segment revenue 0.1 9%
CAG Diagnostics capital… 0.1 9% +74%
Cost of revenue−0.436%
Gross profit0.762% margin+1pp
Research & development−0.16%+0pp
Sales & marketing−0.114%−1pp
G&A−0.110%+0pp
Operating profit0.432% margin+1pp
Tax−0.1
Net profit0.325%+1pp
Filing on EDGAR More quarters of IDXX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters